Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber

This publication has 28 references indexed in Scilit:

• The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine
  Allergy, 2004
• Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study
  Allergy, 2004
• A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit – the Vienna Challenge Chamber (VCC)
  Current Medical Research and Opinion, 2004
• Validation of the classification of ARIA (allergic rhinitis and its impact on asthma)
  Allergy, 2003
• Rupatadine: A new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist
  Drugs of Today, 2003
• Antihistamines in late-phase clinical development for allergic disease
  Expert Opinion on Investigational Drugs, 2002
• Decongestant Activity of Desloratadine in Controlled-Allergen-Exposure Trials
  Clinical Drug Investigation, 2002
• Molecular and cellular mechanisms of allergic disease☆☆☆
  Journal of Allergy and Clinical Immunology, 2001
• Allergic rhinitis: not purely a histamine‐related disease
  Allergy, 2000
• Detection of platelet-activating factor in nasal lavage fluid from patients with pollinosis and experimental animals with nasal allergy.
  Nippon Jibiinkoka Gakkai Kaiho, 1990